MatthewSDavidsMDMMSc

Hematologic Oncology

Associate Professor of Medicine, Harvard Medical School, Director of Clinical Research, Division of Lymphoma, Dana-Farber Cancer Institute

Join to view full profile

Dr. Davids is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Davids' full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-3000

Fax+1 617-632-5822

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2011
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2005 - 2008
Yale School of MedicineClass of 2005

Certifications & Licensure

MA State Medical License 2008 - 2026
CT State Medical License 2022 - 2025
NY State Medical License 2007 - 2009
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Young Scientist Award Lymphoma Foundation of America, 2012

Clinical Trials

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Start of enrollment: 2013 May 16
Completed
Phase 1
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL Start of enrollment: 2014 Jun 27
Active, not recruiting
Phase 1, Phase 2
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2014 Oct 01
Active, not recruiting
Phase 2
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL Start of enrollment: 2014 Nov 01
Completed
Phase 1
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2015 Dec 01
Active, not recruiting
Phase 1
A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome Start of enrollment: 2017 Mar 08
Recruiting
Phase 2
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Start of enrollment: 2018 Jul 12
Recruiting
Phase 1, Phase 2
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL Start of enrollment: 2018 Aug 07
Active, not recruiting
Phase 2
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL Start of enrollment: 2020 Oct 19
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.
Alberto J Arribas, Sara Napoli, Eugenio Gaudio, Charles Herbaux, Eleonora Cannas
Blood Advances. 2024-12-24
Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia.
Abi Vijenthira, Virginia O Volpe, Aswin Sekar, Roberta Santos Azevedo, Mariia Mikhaleva
Blood Advances. 2024-12-10
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva
Journal of Clinical Oncology. 2024-12-07

Journal Articles

The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLL
Matthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood

Abstracts/Posters

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...
Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study
Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)
Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na¥ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)
Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...
Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)
Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL
Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers
Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Other

The Rise of Apoptosis: Targeting Apoptosis in Hematologic Malignancies
Matthew Davids, MD, Blood
https://www.doximity.com/articles/98c8dcba-e43a-4f7a-a7f7-4f3bd29ea5d9
UpToDate, Wolters Kluwer Health - 2013-03-29

Press Mentions

Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax USA - English APAC - Traditional ChineseDecember 10th, 2024
ASH 2024 | Results from Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report USA - English APAC - Traditional ChineseNovember 6th, 2024
Mapping Genetic Evolution from CLL to Richter’s SyndromeJanuary 10th, 2023
Join now to see all